Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.91 SEK | -0.87% | +8.33% | -26.02% |
05-03 | Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.02% | 11.66M | |
+0.60% | 217M |
- Stock Market
- Equities
- NANEXA Stock
- News Nanexa AB
- Nanexa Obtains Swedish Approval to Start Clinical Trial for Myeloma Cancer Medication